The path to eradication of rubella.
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
07 Dec 2023
07 Dec 2023
Historique:
received:
19
09
2023
revised:
27
10
2023
accepted:
04
11
2023
medline:
4
12
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Since 1969, rubella and its harmful effect on fetuses infected in utero can be prevented by rubella vaccine, usually given in combination with measles vaccine. The rubella vaccine is highly protective both in children and in adults including women intending to become pregnant. Owing to the use of combined measles and rubella vaccines, congenital rubella infection has been eliminated from the Western Hemisphere and nearly all of Europe. Such combined vaccination is now being applied throughout the world, posing the possibility of eventual rubella eradication. The existence of viruses of animals related to rubella does not appear to be a barrier to eradication of the human virus. However, persistent rubella virus in infants infected in utero and of immunosuppressed patients with granulomas may pose a problem for eradication. Nevertheless, this review posits that eradication of rubella is now feasible if routine vaccination of infants and surveillance for chronic infection are correctly applied.
Identifiants
pubmed: 37973510
pii: S0264-410X(23)01326-9
doi: 10.1016/j.vaccine.2023.11.014
pii:
doi:
Substances chimiques
Rubella Vaccine
0
Measles Vaccine
0
Measles-Mumps-Rubella Vaccine
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7525-7531Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.